*Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands; †Institute of Cancer Sciences, University of Manchester, United Kingdom; ‡Division of Hematology and Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA; §Division of Gynaecology, European Institute of Oncology, Milan, Italy; ∥Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, TX; ¶Department of Clinical Oncology, Barts Health NHS Trust, London, United Kingdom; #Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; **Department of Gynaecology, Newcastle University and Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom; ††Department of Obstetrics and Gynecology, College of Medicine, Ohio State University, Columbus, OH; ‡‡Department of Gynaecologic Oncology, Royal Women's Hospital, and Melbourne University Dept of Obstetrics and Gynaecology, Australia; §§Department of Obstetrics and Gynecology, Haukeland University Hospital; and Department of Clinical Medicine, University of Bergen, Norway; and ∥∥Department of Radiation Oncology, Sunnybrook Cancer Center, Toronto, Canada.
Int J Gynecol Cancer. 2013 Oct;23(8):1528-34. doi: 10.1097/IGC.0b013e3182a26edb.
The second Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting was held on December 1, 2012, and included international multidisciplinary representatives of the 24 member groups. The aims were to review recent advances in molecular pathology of endometrial cancer, focusing on molecular-based therapy, and to identify key hypotheses and issues to be addressed through international collaborative clinical trials.
Reviews and summaries of current knowledge were presented followed by parallel working group sessions for surgery, adjuvant and systemic therapy, and translational research. Plenary discussions were held to integrate translational and clinical issues, and a final discussion session to agree on key trial concepts.
Proposals to take forward on the following trials were agreed: (1) lymphadenectomy to direct adjuvant treatment in women with high-risk endometrial cancer, including a sentinel node substudy; (2) conservative therapy for low-risk endometrial cancers in morbidly obese women with high surgical risks and for fertility-sparing treatment in premenopausal patients; (3) adjuvant therapy for women with early-stage carcinosarcoma. A proposal was made that a GCIG Early Phase Consortium be developed to serve as an international platform for rapid assessment of biomarkers.
第二次妇科癌症国际协作组（GCIG）子宫内膜癌临床试验计划会议于 2012 年 12 月 1 日举行，包括 24 个成员组的国际多学科代表。会议旨在回顾子宫内膜癌分子病理学的最新进展，重点关注基于分子的治疗，并确定需要通过国际合作临床试验解决的关键假设和问题。
会议进行了当前知识的综述和总结，随后进行了手术、辅助和系统治疗以及转化研究的平行工作组会议。举行了全体讨论以整合转化和临床问题，并举行了最后一次讨论会议以达成关键试验概念的协议。
同意提出以下试验的建议：（1）淋巴结切除术指导高危子宫内膜癌患者的辅助治疗，包括前哨淋巴结亚研究；（2）对于高手术风险的病态肥胖妇女的低危子宫内膜癌和绝经前患者的保留生育力治疗进行保守治疗；（3）早期癌肉瘤患者的辅助治疗。提出了建立 GCIG 早期阶段联合会的建议，作为快速评估生物标志物的国际平台。
